Latest news with #Weblink
Business Wire
23-06-2025
- Business
- Business Wire
Biomarker Collaboration and Licensing Agreements Report 2025: Essential Benchmark Data for Dealmakers - Royalty Rates, Deal Financials, Contract Documents, Royalty Rate Trends
DUBLIN--(BUSINESS WIRE)--The "Biomarker Collaboration and Licensing Deals 2016-2025" has been added to offering. This report contains a comprehensive listing of 545 biomarker deals announced since 2016 including financial terms where available including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Fully revised and updated, the report provides details of biomarker deals from 2016 to 2025. Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the world's leading biopharma companies. The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals. The initial chapters of this report provide an orientation of biomarker dealmaking. The chapters cover an introduction to the report, trends in biomarker dealmaking since 2016, an overview of leading deals by headline value, the top 25 most active companies in biomarker dealmaking, and a detailed review of biomarker deals and partnerships organized by technology type since January 2016. The report also includes numerous tables and figures that illustrate the trends and activities in biomarker deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse biomarker collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type, and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Biomarker Collaboration and Licensing Deals includes: Trends in biomarker dealmaking in the biopharma industry Directory of biomarker deal records covering pharmaceutical and biotechnology The leading biomarker deals by value Most active biomarker licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in biomarker dealmaking 2.1. Introduction 2.2. Biomarker deals over the years 2.3. Most active biomarker dealmakers 2.4. Biomarker deals by deal type 2.5. Biomarker deals by therapy area 2.6. Biomarker deals by industry sector 2.7. Deal terms for biomarker deals 2.7.1 Biomarker deals headline values 2.7.2 Biomarker deal upfront payments 2.7.3 Biomarker deal milestone payments 2.7.4 Biomarker royalty rates Chapter 3 - Leading biomarker deals 3.1. Introduction 3.2. Top biomarker deals by value Chapter 4 - Most active biomarker dealmakers 4.1. Introduction 4.2. Most active biomarker dealmakers 4.3. Most active biomarker deals company profiles Chapter 5 - Biomarker contracts dealmaking directory 5.1. Introduction 5.2. Biomarker contracts dealmaking directory Chapter 6 - Biomarker dealmaking by technology type Companies Featured Abbott Laboratories Abbvie Academic Medical Center Adial Pharmaceuticals Agilent Technologies Amgen Arcus Biosciences Arbor Biotechnologies Amoy Diagnostics Bio-Rad Laboratories Biogen Brigham and Women's Hospital Cedars-Sinai Medical Center ChromaCode Cleveland Clinic Cornell University Danaher Dana-Farber Cancer Institute Defense Advanced Research Projects Agency Duke University Eli Lilly European Commission Freenome Fred Hutchinson Cancer Research Center Gilead Sciences Google H3 Biomedicine Illumina Johns Hopkins University Los Alamos National Laboratory Mayo Clinic MD Anderson Cancer Center Michael J Fox Foundation Microsoft National Institutes of Health Novartis Pennsylvania State University Pfizer QIAGEN Regeneron Pharmaceuticals Roche Tesla Thermo Fisher Scientific University of California, Berkeley University of Cambridge University of Florida University of Oxford University of Toronto Vanderbilt University Yale University For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Business Wire
23-06-2025
- Business
- Business Wire
In-Vitro Diagnostic Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 289 Deals - Upfront, Milestone, Royalties Financial Terms, Company A-Z, Deal Type and Therapy Area
DUBLIN--(BUSINESS WIRE)--The "In Vitro Diagnostic Collaboration and Licensing Deals 2016-2025" has been added to offering. This report contains a comprehensive listing of 289 in vitro diagnostic deals announced since 2016, including financial terms where available, with links to online deal records of actual in vitro diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. In Vitro Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the in vitro diagnostic deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of in vitro diagnostic deals from 2016 to 2025. The report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals. The initial chapters of this report provide an orientation of in vitro diagnostic dealmaking. Chapter 1 provides an introduction to the report, while Chapter 2 offers an overview of the trends in in vitro diagnostic dealmaking since 2016. Chapter 3 highlights the leading in vitro diagnostic deals since 2016, sorted by headline value. Chapter 4 gives a comprehensive listing of the top 25 most active companies in in vitro diagnostic dealmaking, along with a detailed list of deals and available public contract documents. Chapter 5 and Chapter 6 offer a detailed review of deals signed and announced since January 2016, with Chapter 6 focusing specifically on various in vitro diagnostic technology types. The report also includes numerous tables and figures that illustrate trends and activities in in vitro diagnostic dealmaking since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand. In Vitro Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse in vitro diagnostic collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time In Vitro Diagnostic Collaboration and Licensing Deals includes: Trends in in vitro diagnostic dealmaking in the biopharma industry Directory of in vitro diagnostic deal records covering pharmaceutical and biotechnology The leading in vitro diagnostic deals by value Most active in vitro diagnostic licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in in vitro diagnostic dealmaking 2.1. Introduction 2.2. In vitro diagnostic deals over the years 2.3. Most active in vitro diagnostic dealmakers 2.4. In vitro diagnostic deals by deal type 2.5. In vitro diagnostic deals by therapy area 2.6. In vitro diagnostic deals by industry sector 2.7. Deal terms for in vitro diagnostic deals 2.7.1 In vitro diagnostic deals headline values 2.7.2 In vitro diagnostic deal upfront payments 2.7.3 In vitro diagnostic deal milestone payments 2.7.4 In vitro diagnostic royalty rates Chapter 3 - Leading in vitro diagnostic deals 3.1. Introduction 3.2. Top in vitro diagnostic deals by value Chapter 4 - Most active in vitro diagnostic dealmakers 4.1. Introduction 4.2. Most active in vitro diagnostic dealmakers 4.3. Most active in vitro diagnostic deals company profiles Chapter 5 - In vitro diagnostic contracts dealmaking directory 5.1. Introduction 5.2. In vitro diagnostic contracts dealmaking directory Chapter 6 - In vitro diagnostic dealmaking by technology type Deal directory Deal directory - In vitro diagnostic deals by company A-Z Deal directory - In vitro diagnostic deals by deal type Deal directory - In vitro diagnostic deals by therapy area Deal type definitions Companies Featured 2cureX 3M 23andMe Abbott Laboratories Actelion Agilent Technologies Alexion Pharmaceuticals AliveCor Allogene Therapeutics American Type Culture Collection (ATCC) Anixa Biosciences AstraZeneca Avacta Bayer Beckman Coulter Bio-Rad Laboratories bioMerieux Biotage Brigham and Women's Hospital Cardiff University Cepheid Cleveland Clinic Columbia University Danaher Dako Eli Lilly Epizyme Fujirebio Diagnostics Genentech Georgetown University Ginkgo BioWorks Guardant Health Hologic Illumina Inova Diagnostics Invitae Janssen Pharmaceuticals Johns Hopkins University Lexent Bio Massachusetts Institute of Technology Mayo Clinic Medigus Memorial Sloan Kettering Cancer Center Monsanto Novartis OraSure Technologies Oxford Nanopore Technologies PerkinElmer Pfizer Qiagen For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Business Wire
23-06-2025
- Business
- Business Wire
Artificial Intelligence (AI) Collaboration, R&D, and Licensing Agreements Trends Report 2025 with Directory of 959 Deals - Upfront, Milestone, & Royalties Terms, Company, Deal Type and Therapy Area
DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence (AI) Collaboration and Licensing Deals 2019-2025" has been added to offering. This report contains a comprehensive listing of 959 artificial intelligence deals announced since 2019, including financial terms where available, and links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Fully revised and updated, the report provides details of artificial intelligence deals from 2019 to 2025. Artificial Intelligence (AI) Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the artificial intelligence deals entered into by the world's leading biopharma companies. The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence deals. These deals tend to be multicomponent, starting with collaborative R&D and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals. The initial chapters of the report offer an orientation of artificial intelligence dealmaking. It begins with an introduction, followed by an overview of the trends in AI dealmaking since 2019. The chapters then highlight leading AI deals, list the top 25 most active companies in AI dealmaking, and provide detailed reviews of AI deals and partnering agreements, organized by specific AI technology type and available contract documents. The report also includes numerous tables and figures that illustrate the trends and activities in artificial intelligence deal-making since 2019. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand. Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2019 Browse artificial intelligence collaboration and licensing deals Benchmark analysis - identify market value of transactions Financial terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess the suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Artificial Intelligence (AI) Collaboration and Licensing Deals includes: Trends in artificial intelligence dealmaking in the biopharma industry Directory of artificial intelligence deal records covering pharmaceutical and biotechnology The leading artificial intelligence deals by value Most active artificial intelligence licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in artificial intelligence dealmaking 2.1. Introduction 2.2. Artificial intelligence deals over the years 2.3. Most active artificial intelligence dealmakers 2.4. Artificial intelligence deals by deal type 2.5. Artificial intelligence deals by therapy area 2.6. Artificial intelligence deals by industry sector 2.7. Deal terms for artificial intelligence deals 2.7.1 Artificial intelligence deals headline values 2.7.2 Artificial intelligence deal upfront payments 2.7.3 Artificial intelligence deal milestone payments 2.7.4 Artificial intelligence royalty rates Chapter 3 - Leading artificial intelligence deals 3.1. Introduction 3.2. Top artificial intelligence deals by value Chapter 4 - Most active artificial intelligence dealmakers 4.1. Introduction 4.2. Most active artificial intelligence dealmakers 4.3. Most active artificial intelligence deals company profiles Chapter 5 - Artificial intelligence contracts dealmaking directory 5.1. Introduction 5.2. Artificial intelligence contracts dealmaking directory Chapter 6 - Artificial intelligence dealmaking by technology type Deal directory Deal directory - Artificial intelligence deals by company A-Z Deal directory - Artificial intelligence deals by deal type Deal directory - Artificial intelligence deals by therapy area Deal type definitions Companies Featured 3M ACT Therapeutics AdventHealth AbbVie Amgen Apple Inc. Alphabet Inc. Amazon Web Services General Electric IBM Microsoft Oracle Pfizer Tata Consultancy Services JP Morgan Chase Goldman Sachs Boeing Hewlett Packard Enterprise Procter & Gamble Johnson & Johnson Delta Air Lines Ford Motor Company Facebook NVIDIA Corporation Cisco Systems Intel Corporation Verizon Communications Coca-Cola Company Samsung Electronics Tesla, Inc. ExxonMobil Walmart PepsiCo Disney Adobe Systems Salesforce Nike Unilever Red Hat Siemens AG American Express Berkshire Hathaway Starbucks Alphabet Inc. Arm Holdings LinkedIn Airbnb Netflix Spotify SpaceX Uber Technologies For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Yahoo
17-06-2025
- Business
- Yahoo
Cancer Diagnostic Collaboration, R&D, and Licensing Deals Analysis Report 2025: Access Actual Deals Signed by the World's Leading Biopharma Companies Since 2018
Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Cancer Diagnostic Collaboration and Licensing Deals 2018-2025" report has been added to report contains a comprehensive listing of 724 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Fully revised and updated, the report provides details of cancer diagnostic deals from 2018 to 2025. The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the world's leading biopharma initial chapters of this report provide an orientation of cancer diagnostic 1 provides an introduction to the 2 provides an overview of the trends in cancer diagnostic dealmaking since 3 provides an overview of the leading cancer diagnostic deals since 2018. Deals are listed by headline 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2018, where a contract document is available in the public 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2018. The chapter is organized by specific cancer diagnostic technology type in report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2018 Browse cancer diagnostic collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Cancer Diagnostic Collaboration and Licensing Deals includes: Trends in cancer diagnostic dealmaking in the biopharma industry Directory of cancer diagnostic deal records covering pharmaceutical and biotechnology The leading cancer diagnostic deals by value Most active cancer diagnostic licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in cancer diagnostic dealmaking2.1. Introduction2.2. Cancer diagnostic deals over the years2.3. Most active cancer diagnostic dealmakers2.4. Cancer diagnostic deals by deal type2.5. Cancer diagnostic deals by therapy area2.6. Cancer diagnostic deals by industry sector2.7. Deal terms for cancer diagnostic deals2.7.1 Cancer diagnostic deals headline values2.7.2 Cancer diagnostic deal upfront payments2.7.3 Cancer diagnostic deal milestone payments2.7.4 Cancer diagnostic royalty ratesChapter 3 - Leading cancer diagnostic deals3.1. Introduction3.2. Top cancer diagnostic deals by valueChapter 4 - Most active cancer diagnostic dealmakers4.1. Introduction4.2. Most active cancer diagnostic dealmakers4.3. Most active cancer diagnostic deals company profilesChapter 5 - Cancer diagnostic contracts dealmaking directory5.1. Introduction5.2. Cancer diagnostic contracts dealmaking directoryChapter 6 - Cancer diagnostic dealmaking by technology type For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
Gene Therapy Collaboration and Licensing Deals Report and Directory 2025: Explore the Financials Behind 787 Gene Therapy Licensing Deals from 2016-2025
The Gene Therapy Collaboration and Licencing Deals report features 787 deals with financial terms and SEC contracts. Explore trends in R&D partnerships, commercialization strategies, and IP structures. Ideal for benchmarking deal terms, assessing opportunities, and streamlining due diligence in the gene therapy space. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" report has been added to report contains a comprehensive listing of 787 gene therapy deals announced since 2016, including financial terms where available, and links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the world's leading biopharma revised and updated, the report provides details of gene therapy deals from 2016 to report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of report includes collaboration, development, research and licensing initial chapters of this report provide an orientation of gene therapy dealmaking. Chapter 1 introduces the report, while Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016. Chapter 3 offers a summary of the leading gene therapy deals since 2016, listed by headline value. Chapter 4 lists the top 25 most active companies in gene therapy dealmaking, with summaries and comprehensive listings of deals. Chapter 5 and Chapter 6 offer detailed reviews of gene therapy deals and partnering deals announced since Jan 2016, focusing on contract documents in the public domain and specific gene therapy technologies report also includes numerous tables and figures that illustrate the trends and activities in gene therapy deal making since 2016. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on Therapy Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse gene therapy collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeGene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies Therapy Collaboration and Licensing Deals includes: Trends in gene therapy dealmaking in the biopharma industry Directory of gene therapy deal records covering pharmaceutical and biotechnology The leading gene therapy deals by value Most active gene therapy licensing dealmakers Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered:Chapter 1 - IntroductionChapter 2 - Trends in gene therapy dealmaking2.1. Introduction2.2. Gene therapy deals over the years2.3. Most active gene therapy dealmakers2.4. Gene therapy deals by deal type2.5. Gene therapy deals by therapy area2.6. Gene therapy deals by industry sector2.7. Deal terms for gene therapy deals2.7.1 Gene therapy deals headline values2.7.2 Gene therapy deal upfront payments2.7.3 Gene therapy deal milestone payments2.7.4 Gene therapy royalty ratesChapter 3 - Leading gene therapy deals3.1. Introduction3.2. Top gene therapy deals by valueChapter 4 - Most active gene therapy dealmakers4.1. Introduction4.2. Most active gene therapy dealmakers4.3. Most active gene therapy deals company profilesChapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directoryChapter 6 - Gene therapy dealmaking by technology typeDeal directory Deal directory - Gene therapy deals by company A-Z Deal directory - Gene therapy deals by deal type Deal directory - Gene therapy deals by therapy area For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
